

**Prof. Dr. med. Marco Valgimigli**  
**Inselspital Bern, Switzerland**



Prof. Marco Valgimigli's research has influenced both the European & USA guidelines for clinical practice, impacting on coronary stent selection as well as indications and regimens of various anti-thrombotic drugs & choice of access site during coronary intervention. Initially member/reviewer of multiple ESC guidelines task forces, and he then acted as chair of the European focused update guidelines on dual antiplatelet therapy. As clinical trialist & PI on multiple investigator initiated global prospective randomized studies, including Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates (ZEUS) & the Minimizing Adverse Hemorrhagic Events by Transradial Access Site & Systemic Implementation of Angiox (MATRIX) program with 3 different randomization schemes in a quasi-factorial study design. Valgimigli conceived & designed both studies. Identified the grant givers, secured funding for their conduct, oversaw sponsor & clinical research activities & published the results in multiple peer review journals.

In the field of personalized medicine, Valgimigli recently published in the Lancet journal the development & external validation of the PRECISE DAPT score, which shows the discrimination between net clinical benefits versus net clinical harm in regards to a prolonged course of DAPT therapy in largely unselected patients undergoing PCI.

Prof. Valgimigli's research focus has also embraced the field of inflammation and its interaction with reactive oxygen species in patients with prior MI progressing or not progressing towards over heart failure as well the characterization of bone marrow stem cells mobilization in relation to an acute ischemic or non-ischemic myocardial injury or in patients with over heart failure in relation to the severity of the disease. Finally, Valgimigli pioneered the field of bone marrow stem cells mobilization with the use of granulocyte colony stimulating factor in order to promote myocardial regeneration and repair in patients having suffered from MI.

September 2018